Elicio Therapeutics, Inc.
- Jurisdiction
United States - ISIN
US28657F1030 (ELTX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€38.33M - EBIT margin
0.0% - Net income
-€46.88M - Net margin
0.0%
Statement period: - (published )
Dividends
No dividend payouts